Rapid Dose Therapeutics Statistics
Total Valuation
CSE:DOSE has a market cap or net worth of CAD 20.69 million. The enterprise value is 26.01 million.
| Market Cap | 20.69M |
| Enterprise Value | 26.01M |
Important Dates
The next estimated earnings date is Thursday, January 29, 2026.
| Earnings Date | Jan 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CSE:DOSE has 133.46 million shares outstanding. The number of shares has increased by 33.83% in one year.
| Current Share Class | 133.46M |
| Shares Outstanding | 133.46M |
| Shares Change (YoY) | +33.83% |
| Shares Change (QoQ) | -37.17% |
| Owned by Insiders (%) | 15.12% |
| Owned by Institutions (%) | n/a |
| Float | 113.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.88 |
| PB Ratio | -3.52 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.66 |
| EV / Sales | 9.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -24.64 |
Financial Position
The company has a current ratio of 0.13
| Current Ratio | 0.13 |
| Quick Ratio | 0.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.06 |
| Interest Coverage | -2.87 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -71.38% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 93.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.88 |
| Inventory Turnover | 5.32 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.33% in the last 52 weeks. The beta is -0.70, so CSE:DOSE's price volatility has been lower than the market average.
| Beta (5Y) | -0.70 |
| 52-Week Price Change | -33.33% |
| 50-Day Moving Average | 0.16 |
| 200-Day Moving Average | 0.19 |
| Relative Strength Index (RSI) | 47.88 |
| Average Volume (20 Days) | 24,514 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CSE:DOSE had revenue of CAD 2.63 million and -4.60 million in losses. Loss per share was -0.03.
| Revenue | 2.63M |
| Gross Profit | 1.36M |
| Operating Income | -3.41M |
| Pretax Income | -4.60M |
| Net Income | -4.60M |
| EBITDA | -3.05M |
| EBIT | -3.41M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 8,570 in cash and 5.34 million in debt, giving a net cash position of -5.33 million or -0.04 per share.
| Cash & Cash Equivalents | 8,570 |
| Total Debt | 5.34M |
| Net Cash | -5.33M |
| Net Cash Per Share | -0.04 |
| Equity (Book Value) | -5.88M |
| Book Value Per Share | -0.04 |
| Working Capital | -6.88M |
Cash Flow
In the last 12 months, operating cash flow was -1.05 million and capital expenditures -5,740, giving a free cash flow of -1.06 million.
| Operating Cash Flow | -1.05M |
| Capital Expenditures | -5,740 |
| Free Cash Flow | -1.06M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 51.93%, with operating and profit margins of -129.74% and -175.00%.
| Gross Margin | 51.93% |
| Operating Margin | -129.74% |
| Pretax Margin | -175.00% |
| Profit Margin | -175.00% |
| EBITDA Margin | -116.29% |
| EBIT Margin | -129.74% |
| FCF Margin | n/a |
Dividends & Yields
CSE:DOSE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.83% |
| Shareholder Yield | -33.83% |
| Earnings Yield | -22.21% |
| FCF Yield | -5.10% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CSE:DOSE has an Altman Z-Score of -17.6 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.6 |
| Piotroski F-Score | 2 |